In a recent video interview with Applied Clinical Trials, Marc Buyse, ScD, founder and CEO of IDDI, discussed how growing trial complexity is creating new challenges for data conf ...
Hello, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...
8h
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
The Citizens Life Sciences Conference 2026 March 10, 2026 4:00 PM EDTCompany ParticipantsMark Jacobson - Chief ...
Compare the top Series 63 exam prep courses and find the best match for your learning style to build confidence and pass your ...
Allogene Therapeutics Inc (ALLO) extends its cash runway into 2028 while focusing on pivotal clinical milestones and innovative treatment strategies.
Background The presence of a coincident intracranial aneurysm (CIA) on the target vessel of patients undergoing mechanical thrombectomy (MT) for acute ischemic stroke (AIS) poses challenges, as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results